Slide 1: Q3 2023 Financial Results and Business Update
Q3 2023 Financial Results and Business Update 14 November 2023
Slide 2: Disclaimer on Forward-Looking Information and Risk Factors
Disclaimer on Forward-Looking Information and Risk Factors This document has been prepared by Innate Pharma S.A. (the “Company”) solely for the purposes of a presentation to investors concerning the Company. This document is not to be reproduced by any person, nor to be distributed. 2
Slide 3: Speakers on Today's Call
Speakers on Today’s Call Mondher Mahjoubi Sonia Quaratino Yannis Morel Frédéric Lombard MD MD PhD MBA Chief Executive Officer Chief Medical Officer Head of Business Development Chief Financial Officer and Product Portfolio Strategy Chairman of the Executive Board
Slide 4: Scientific innovation drives our strategy
Scientific innovation drives our strategy Our ambition – leverage our scientific know-how in innate Advance our Build a sustainable Drive near-term value immunity and antibody engineering to innovative business through with lacutamab develop cancer drugs that improve the Drive near-term value pipeli
Slide 5: Our robust pipeline of proprietary & partnered assets
Our robust pipeline of proprietary & partnered assets Program Target Indication Pre-Clinical Phase 1 Phase 2 Phase 3 Upcoming Milestone Sezary syndrome / MF TELLOMAK (FDA FAST TRACK/EMA PRIME DESIGNATION) ASH/ Final data H2 2023 Lacutamab KIR3DL2 PTCL KILT Phase 2 / Phase 1b IST with LYSA Proprietar
Slide 6: Lacutamab | Development strategy
LACUTAMAB Lacutamab | Development strategy A potential new standard of care in the T-cell lymphomas expressing KIR3DL2 Cutaneous T cell lymphoma TELLOMAK Sézary syndrome Phase 2 Trial Sézary syndrome 80-200 patients Phase 2 ~90% KIR3DL2 expression Cohort 1 (N~60) 3 cohorts (N~100) ASH 2023 Minimum o
Slide 7: ASH 2023 abstract - Lacutamab Sézary syndrome Phase 2 data
LACUTAMAB ASH 2023 abstract - Lacutamab Sézary syndrome Phase 2 data Lacutamab in Patients with Relapsed and Refractory Sézary Syndrome: Results from the TELLOMAK Phase 2 Trial Sézary Patient baseline characteristics 56 post mogamulizumab patients with advanced, highly refractory and heavily pre-tre
Slide 8: Monalizumab development in progress of Phases 2 and 3 trials
MONALIZUMAB Monalizumab development in progress of Phases 2 and 3 trials Covering early stages of lung cancer Stages of the disease NeoCOAST* Data presented: 2022 NeoCOAST-2* 30% major pathological Patients with Stage II to IIIB NSCLC NSCLC response vs. 11% durvalumab. Monalizumab + durvalumab + che
Slide 9: ANKET: A versatile, fit-for-purpose technology
ANKET® Proprietary NK cell engager platform Harnesses NK cell effector functions against cancer cells, through the most conserved activating receptor on NK cells: NKp46. Provides proliferation and activation signals targeted to NK cells. Demonstrates better anti-tumor efficacy than approved benchmar
Slide 10: ANKET NK cell engager molecules have the potential to strongly control tumor proliferation
ANKET® ANKET® NK cell engager molecules have the potential to strongly control tumor proliferation via the harnessing of NK cells Growing clinical pipeline Differentiated MoA SAR443579 / IPH6101 (CD123) Phase 1 / 2 ANKET3 Nature Biotechnology SAR’514 / IPH6401 (BCMA) Phase 1 / 2 January 2023 IPH6501
Slide 11: SAR443579 / IPH6101 promising preliminary single agent clinical activity in R/R AML
ANKET® SAR443579 / IPH6101 promising preliminary single agent clinical activity in R/R AML SAR443579 / IPH6101 is a trifunctional anti-CD123 NKp46xCD16 NK cell engager PHASE 1 / 2 underway ESMO presentation (data cut-off: Aug 7, 2023) 82 patients to be enrolled with various hematological malignancie
Slide 12: Strategic partnership between Sanofi and Innate
ANKET® Strategic partnership between Sanofi and Innate Three molecules licensed to Sanofi plus two undisclosed targets under options SAR’579 / IPH6101 SAR’514 / IPH6401 IPH62 OPTION Ongoing CD123 BCMA B7-H3 2 undisclosed programs Phase 1 / 2 in AML Phase 1 / 2 in Multiple Myeloma Research targets Pa
Slide 13: Our antibody platform contributes to the R&D engine with novel ADC assets
ADC Our antibody platform contributes to the R&D engine with novel assets under Antibody Drug Conjugates formats ADC Research pipeline – Lead asset at pre-IND stage IPH45 (Nectin-4) Pre-IND IPH43 (MICA) Phase 1 Research Target (Tumor antigen) Research Target (Coeliac disease) Research
Slide 14: IPH45 (Nectin-4)
ADC IPH45 (Nectin-4) A next generation ADC to maximize the Nectin-4 opportunity across multiple tumor types IPH45 overcomes resistance to EV in preclinical models • Differentiated epitope non-competing with EV IPH45 key scientific • Stable linker with high hydrophilicity Mean tumor volume (mm3) SEM
Slide 15: Presentations at the ASH 2023 Annual Meeting
Presentations at the ASH 2023 Annual Meeting What will be presented? Lacutamab Phase 2 Sézay syndrome Lacutamab Phase 1b PTCL initial data SAR443579 (CD123 ANKET) (Sanofi) Innate Pharma lacutamab KOL analyst & investor call December TBC - San Diego
Slide 16: Newsflow and upcoming catalysts
Newsflow and upcoming catalysts • Monalizumab PACIFIC-9 | Phase 3 readout (AZ) Delivering across our strategic objectives • Monalizumab NeoCOAST-2 | Phase 2 readout (AZ) • IPH5201(CD39) MATISSE | Phase 2 readout (AZ) • SAR’579 / IPH6101 ANKET ® (CD123) | Phase 1 • SAR’579 / IPH6101 ANKET® (CD123) |
Slide 17: Key Takeaways
Key Takeaways Create value for patients and shareholders Strategic Priorities Robust pipeline of Antibody engineering capabilities Advancing lacutamab Maximizing ANKET® platform Continuing to explore ADC Early R&D focus to drive value Track record of strategic partnerships through later stage AstraZ
Slide 18: Thank you
Thank you www.innate-pharma.com investors@innate-pharma.fr EURONEXT : IPH.PA NASDAQ : IPHA